Skip to main content

Scinai Immunotherapeutics Ltd.

SCNI
Exchange
Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
SEC CIK
0001611747

No open-market purchases or sales by Scinai Immunotherapeutics Ltd. insiders were filed in the last 90 days; 11 institutions reported holding it in 13F filings for Q2 2026, worth $49.1K in total; no superinvestor holds it.

Key figures

Insider buysOpen market, last 90 days
0
Insider sellsOpen market, last 90 days
0
13F holdersQ2 2026, +7 vs. previous quarter
11
13F valueReported value at the end of Q2 2026
$49.1K
Superinvestors holdingAt the end of Q2 2026
0

Price chart

Superinvestors holding SCNI, Q2 2026

Go to the superinvestors tab

No superinvestor reported holding SCNI at the end of Q2 2026.

Latest insider trades

Open-market purchases and sales by Scinai Immunotherapeutics Ltd. insiders from Form 4, newest first.

See all insider trades

No open-market purchases or sales by Scinai Immunotherapeutics Ltd. insiders are on file.

Top 10 13F holders, Q2 2026

The largest institutional positions in Scinai Immunotherapeutics Ltd. at the end of Q2 2026; share changes are against Q1 2026.

See all 11 holders
Institutions holding SCNI in Q2 2026
InstitutionSharesValue% of portfolioChange in sharesAction
Citadel Advisors LLC62,257$15.7K0.00%+62,257New
Armistice Capital, LLC35,942$9.08K0.00%+35,942New
Virtu Financial LLC19,485$5.00K0.00%+19,485New
StoneX Group Inc.13,092$4.56K0.00%+13,092New
XTX Topco Ltd16,764$4.24K0.00%−7,277−30.3%Reduced
Rhumbline Advisers13,513$3.42K0.00%+11,635+619.5%Added
Captrust Financial Advisors12,035$3.04K0.00%+12,035New
HRT Financial LP12,088$3.00K0.00%+12,088New
UBS Group AG3,955$1.00K0.00%+3,036+330.4%Added
Morgan Stanley58$150.00%00.0%Unchanged